SOURCE: Horizon Pharma plc

Horizon Pharma plc

September 23, 2014 16:05 ET

Horizon Pharma plc to Host Friedreich's Ataxia Analyst Day on October 13, 2014

ACTIMMUNE® (Interferon gamma-1b) Phase 2 Results in Friedreich's Ataxia to Be Presented

DUBLIN, IRELAND--(Marketwired - Sep 23, 2014) - Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, will host an Analyst Day on Monday, October 13, 2014 at the Crowne Plaza Valley Forge in King of Prussia, PA.  A live audio webcast and accompanying slide presentations will be available at http://ir.horizon-pharma.com.  

The Horizon Pharma Analyst Day is being held following the Children's Hospital of Philadelphia's 7th Annual Friedreich's Ataxia Symposium at the Crown Plaza Valley Forge.    

Presentations by members of Friedreich's Ataxia Research Alliance (FARA) will discuss Friedreich's ataxia (FA) from the patient, caregiver and advocate perspective and review the ACTIMMUNE® FA Phase 2 clinical trial results.  In addition, Horizon's senior management team will review the clinical, regulatory and commercial plans for ACTIMMUNE and other corporate strategies. 

The Horizon Pharma presentation will start promptly at 5:00 pm EDT and is expected to end by 6:30 pm EDT followed by a Q&A session.  The live webcast and replay may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com.  Please connect to the Company's website at least 15 minutes prior to the presentation start time to hear the live webcast and to ensure adequate time for any software download that may be needed to access the webcast.  An archived webcast replay of the event will be available approximately four hours following the event at http://ir.horizon-pharma.com and will remain available for 10 days.

About Horizon Pharma plc

Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs.  The company markets a portfolio of products in arthritis, inflammation and orphan diseases.  The Company's U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole).  Horizon's global headquarters are in Dublin, Ireland.  For more information, please visit www.horizonpharma.com.

Contact Information

  • Contacts:
    Company:
    Elizabeth M. Higashi, CFA
    Vice President, Investor Relations
    Email Contact
    1-224-383-3000

    Investors:
    Ami Bavishi
    Email Contact
    212-213-0006 ext. 344

    Media:
    E. Blair Clark-Schoeb
    Email Contact
    917-432-9275